[Cefepime/amikacin in the empirical antibacterial therapy for patients with hemoblastosis of different forms].
The results of the use of cefepime (Maxipime) combination with amikacin vs ceftriaxon combination with amikacin in the treatment of 80 patients with different forms of hemoblastosis are presented. Severe infectious complications in the patients were associated with prolonged and deep neutropenia during inductive or antirelapsing chemotherapy. All the patients in the trial were from the group of high risk of infectious complications with the blood neutrophil count under 100 cells/microliter. The duration of neutropenia averaged 12 days (7 to 15). The average period of the treatment with cefepime and amikacin equaled to 13 days (8 to 16). The treatment with cefepime + amikacin was successful in 38 out of 40 patients (95%). The average period of the treatment with ceftriaxon and amikacin equaled to 14 days (7 to 18). The efficacy of the treatment with ceftriaxon + amikacin was 60% (24 patients out of 40).
Chudanova
T V
TV
Russian Research Institute of Hematology and Transfusiology, Ministry of Public Health of the Russian Federation, St. Petersburg.
Abdulkadyrov
K M
KM
Chebotkevich
V N
VN
D000583:Amikacin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000097:blood / Q000517:prevention & control*; D000077723:Cefepime; D002443:Ceftriaxone / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007958:Leukocyte Count; D009503:Neutropenia / Q000209:etiology; D009504:Neutrophils; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone; D000077723:Cefepime; D000583:Amikacin